These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35717429)

  • 1. CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors.
    Caruso D; Polici M; Rinzivillo M; Zerunian M; Nacci I; Marasco M; Magi L; Tarallo M; Gargiulo S; Iannicelli E; Annibale B; Laghi A; Panzuto F
    Radiol Med; 2022 Jul; 127(7):691-701. PubMed ID: 35717429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients.
    Karim H; Winkelmann M; Grawe F; Völter F; Auernhammer C; Rübenthaler J; Ricke J; Ingenerf M; Schmid-Tannwald C
    Radiol Oncol; 2024 Sep; 58(3):348-356. PubMed ID: 38861687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of the characteristics of aggressiveness of pancreatic neuroendocrine neoplasms (PanNENs) based on CT radiomic features.
    Mori M; Palumbo D; Muffatti F; Partelli S; Mushtaq J; Andreasi V; Prato F; Ubeira MG; Palazzo G; Falconi M; Fiorino C; De Cobelli F
    Eur Radiol; 2023 Jun; 33(6):4412-4421. PubMed ID: 36547673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a radiomic model to predict tumor grade.
    Chiti G; Grazzini G; Flammia F; Matteuzzi B; Tortoli P; Bettarini S; Pasqualini E; Granata V; Busoni S; Messserini L; Pradella S; Massi D; Miele V
    Radiol Med; 2022 Sep; 127(9):928-938. PubMed ID: 35917099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate non-invasive grading of nonfunctional pancreatic neuroendocrine tumors with a CT derived radiomics signature.
    Javed AA; Zhu Z; Kinny-Köster B; Habib JR; Kawamoto S; Hruban RH; Fishman EK; Wolfgang CL; He J; Chu LC
    Diagn Interv Imaging; 2024 Jan; 105(1):33-39. PubMed ID: 37598013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study.
    Gu D; Hu Y; Ding H; Wei J; Chen K; Liu H; Zeng M; Tian J
    Eur Radiol; 2019 Dec; 29(12):6880-6890. PubMed ID: 31227882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of clinical, radiomic, and "delta" radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma.
    Krishna S; Sertic A; Liu ZA; Liu Z; Darling GE; Yeung J; Wong R; Chen EX; Kalimuthu S; Allen MJ; Suzuki C; Panov E; Ma LX; Bach Y; Jang RW; Swallow CJ; Brar S; Elimova E; Veit-Haibach P
    Front Oncol; 2023; 13():892393. PubMed ID: 37645426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiomic Cancer Hallmarks to Identify High-Risk Patients in Non-Metastatic Colon Cancer.
    Caruso D; Polici M; Zerunian M; Del Gaudio A; Parri E; Giallorenzi MA; De Santis D; Tarantino G; Tarallo M; Dentice di Accadia FM; Iannicelli E; Garbarino GM; Canali G; Mercantini P; Fiori E; Laghi A
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Special issue "The advance of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors.
    Chen L; Wang W; Jin K; Yuan B; Tan H; Sun J; Guo Y; Luo Y; Feng ST; Yu X; Chen MH; Chen J
    Int J Cancer; 2023 Jan; 152(1):90-99. PubMed ID: 36111424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT-based radiomic features predict tumor grading and have prognostic value in patients with soft tissue sarcomas treated with neoadjuvant radiation therapy.
    Peeken JC; Bernhofer M; Spraker MB; Pfeiffer D; Devecka M; Thamer A; Shouman MA; Ott A; Nüsslin F; Mayr NA; Rost B; Nyflot MJ; Combs SE
    Radiother Oncol; 2019 Jun; 135():187-196. PubMed ID: 30961895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preoperative computed tomography radiomics model to predict disease-free survival in patients with pancreatic neuroendocrine tumors.
    Homps M; Soyer P; Coriat R; Dermine S; Pellat A; Fuks D; Marchese U; Terris B; Groussin L; Dohan A; Barat M
    Eur J Endocrinol; 2023 Oct; 189(4):476-484. PubMed ID: 37787635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
    Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
    Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
    Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma.
    Xu X; Zhang HL; Liu QP; Sun SW; Zhang J; Zhu FP; Yang G; Yan X; Zhang YD; Liu XS
    J Hepatol; 2019 Jun; 70(6):1133-1144. PubMed ID: 30876945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiphase computed tomography radiomics of pancreatic intraductal papillary mucinous neoplasms to predict malignancy.
    Polk SL; Choi JW; McGettigan MJ; Rose T; Ahmed A; Kim J; Jiang K; Balagurunathan Y; Qi J; Farah PT; Rathi A; Permuth JB; Jeong D
    World J Gastroenterol; 2020 Jun; 26(24):3458-3471. PubMed ID: 32655269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
    Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors.
    Benslama N; Bollard J; Vercherat C; Massoma P; Roche C; Hervieu V; Peron J; Lombard-Bohas C; Scoazec JY; Walter T
    Invest New Drugs; 2016 Oct; 34(5):654-62. PubMed ID: 27230034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.